anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: The study aimed to investigate the impact of adjuvant chemotherapy on time to recurrence (TTR) and overall survival (OS) in patients with histologic variants of upper tract urothelial carcinoma (VUTUC) following radical nephroureterectomy (RNU).
MATERIALS AND METHODS: A retrospective review of 131 VUTUC patients' medical records, from a pool of 368 non-metastatic localized or locally advanced UTUC cases, treated at a single tertiary referral center between January 2011 and January 2021. The intervention was adjuvant chemotherapy administration post-RNU. TTR and OS were evaluated using Kaplan-Meier and Cox proportional hazard regression, covariates adjusted for age, postoperative GFR, history of neoadjuvant chemotherapy, T and N stage with stabilized inverse probability of treatment weighting (sIPTW).
RESULTS: The application of adjuvant chemotherapy showed a significant extension in TTR (P = .01), but no substantial impact on OS (P = .19) after sIPTW adjustment for covariates. Multivariate analysis revealed adjuvant chemotherapy, tumor size, and lymphovascular invasion as significant prognostic factors for TTR. In contrast, only tumor size and perineural invasion were significant for OS. Adjuvant chemotherapy reduced the progression risk in certain VUTUC subtypes (squamous or glandular/micropapillary), but not in sarcomatoid variants.
CONCLUSIONS: Adjuvant chemotherapy appears to improve TTR, albeit without a significant effect on OS, in nonmetastatic localized and locally advanced VUTUC patients post-RNU. While beneficial to some VUTUC subtypes, it did not yield significant advantages for sarcomatoid variants. Despite adjustments for known confounders, the study's findings may be subject to potential selection bias and unmeasured confounding factors.
Participants randomized to the waitlist control group will complete the same assessment protocol at the time of randomization (Baseline) and again 6 weeks later. They will then be invited to begin treatment and will repeat the assessments at posttest and again at 14 and 26-week follow-up (for a total of 5 assessments).
550,746. Hair-waving lotions. BAKER, M., and FREEDMAN, L. (trading as MAURICE, L., [Firm of]). Jan. 29, 1942. [Class 131] A hair waving lotion comprises an aqueous solution or emulsion of one or more of the sulphites of sodium, potassium, magnesium or ammonium, ammonium and a viscous carrier consisting of one or more of the higher fatty acids, or higher fatty alcohols or esters derived from such acids or alcohols, more particularly the stearates, palmitates, laurates and oleates subject always to the qualification that the same shall be stable when used in alkaline solutions or emulsions not only at the normal temperatures but also at the elevated temperatures to which the reagents are subjected during the process of permanently waving the hair. A preferred solution comprises sodium sulphite, sulphonated castor oil, ammonia, glyceryl mono-stearate, and water in the proportions mentioned in the Specification. A number of compounds suitable to act as the viscous carrier are mentioned in the Specification.
The invention discloses a BODIPY photosensitizer and a preparation method and application thereof. The BODIPY photosensitizer is a compound with a structure shown in a formula (I). The preparation method comprises the following steps: s1, reacting p-hydroxybenzaldehyde with 1, 6-dibromohexane; s2, reacting a compound with a structure shown in a formula (IV) with 2, 4-dimethylpyrrole under a protective atmosphere; s3, compound with structure of formula (III) and I 2 /HIO 3 Iodination reaction occurs; s4, carrying out Knoevenagel condensation reaction on the compound with the structure shown in the formula (II) and 2-thiophenecarboxaldehyde to obtain the compound with the structure shown in the formula (I). The compound has application in photodynamic therapy medicines. The yield of the singlet oxygen quantum reaches 78%, and the singlet oxygen quantum can efficiently sensitize triplet oxygen atoms in the air to generate a large amount of singlet oxygen under the excitation of a low-power light source. Wherein the compounds of formulae (I), (II), (III) and (IV) have the following structures:
FIELD: microbiology, vaccines. SUBSTANCE: invention relates to preparing thermolabile enterotoxin (LT-enterotoxin) and anatoxin of Enterobacter agglomerans used for production of vaccines. Strain Enterobacter agglomerans N 5356 is isolated from patient feces with foot mycosis, deposited in the Collection of the State Scientific- -Research Institute of standardization and control of medicinal biological preparations at registration number 257. Strain Enterobacter agglomerans GISK N 256 shows the following traits. In culturing in the usual nutrient media at 37 C the strain grows on surface of nutrient medium forming typical isolated colonies of yellow color shade. In culturing in Hottinger broth (pH 7.2) at 37 C for 24 h the strain causes uniform turbidity accompanying with precipitate formation. After subplantar administration of 0.05 ml of centifugate of 20 h broth culture in mice (weight is 15-16 g) in the dose above 95 mg paw edema is developed. Intranasal administration of 0.05 mg of 20 h broth culture in mouse males (weight is 15-16 g) results to the death of animals for 4 h at symptoms of tonic seizures and asphyxia. Intracutaneous administration of 300 mln of microbe cells of 20 h broth culture in rabbit results to development of skin necrosis (diameter is 3.0 cm). In experiment with rabbit small intestine loop after administration of 500 mln cells of 20 h broth culture the positive effect is observed (V/L = 1.2). Centrifugate of 20 h broth culture heated preliminarily at 56 C for 45 min induces paw edema in mice (dose is below 30 mg) but it does not induce skin necrosis in rabbit. Preliminarily heated at 100 C 20 h broth culture does not induce fluid accumulation in rabbit isolated small intestine loop (V/L = 0.3). Media for multiplication of bacterial cells: Hottinger broth (pH 7.2) containing 5% of rabbit erythrocytes at 37 C for 24 h. Genetic traits: Hly + ,Ent + ,MS + ,MR + . Strain shows resistance to penicillin, tetracycline, erythromycin, levomycetin, carbencillin, rifampicin and oleandomycin. Strain Enterobacter agglomerans GISK N 257 shows the enhanced toxin-producing capability. EFFECT: strain indicated above, valuable properties, enhanced production of toxins. 1 tbl, 2 ex
Each participant will follow 24 therapy sessions (2 x 1.5 hours/week). The experimental group will perform a multimodal HIT protocol. Cardiorespiratory training will consist of a high-intensity interval training protocol on a cycle ergometer. After a five-minute warm-up, interval training will start, consisting of five one-minute bouts (110 RPM at 100% VO2max workload), separated by one minute of active rest (75 RPM at 50% VO2max workload). Limb strength training will consist of a circuit of three upper-body (vertical traction, chest press, arm curl) and three lower-body exercises (leg curl, leg press, leg extension) executed at 80% of the one repetition maximum. Core muscle training will consist of a circuit of six static core exercises (glute bridge, glute clam, superman back extension, adapted plank, adapted side plank, shoulder retraction with hip hinge) at 60% of the maximal voluntary contraction.
The present invention relates to medicine for treating acute and chronic tonsillitis. The medicine is composed of the raw materials with the following parts by weight: 30 to 40 shares of dandelion, 10 to 20 shares of chrysanthemum flower, 10 to 20 shares of dry lotus rhizome node, and 4 to 8 shares of viola herb. After the raw materials are added with water, decoction and residue filtration are carried out. The present invention completely uses food, and accordingly, the present invention which does not have toxic side effects has the functions of the relief of inflammation and detumescence, and the immunity of patients can be increased. Accordingly, the present invention obtains the function of treating acute and chronic tonsillitis. In the recent five years, after 53 patients with the disease symptom take the medicine, the effective rate is 90%.
Hypoxic-ischemic encephalopathy (HIE), resulting from a lack of blood flow and oxygen before or during newborn delivery, is a leading cause of cerebral palsy and neurological disability in children. Therapeutic hypothermia (TH), the current standard of care in HIE, is only beneficial in 1 of 7-8 cases. Therefore, there is a critical need for more efficient treatments. We have previously reported that omega-3 (n-3) fatty acids (FA) carried by triglyceride (TG) lipid emulsions provide neuroprotection after experimental hypoxic-ischemic (HI) injury in neonatal mice. Herein, we propose a novel acute therapeutic approach using an n-3 diglyceride (DG) lipid emulsions. Importantly, n-3 DG preparations had much smaller particle size compared to commercially available or lab-made n-3 TG emulsions. We showed that n-3 DG molecules have the advantage of incorporating at substantially higher levels than n-3 TG into an in vitro model of phospholipid membranes. We also observed that n-3 DG after parenteral administration in neonatal mice reaches the bloodstream more rapidly than n-3 TG. Using neonatal HI brain injury models in mice and rats, we found that n-3 DG emulsions provide superior neuroprotection than n-3 TG emulsions or TH in decreasing brain infarct size. Additionally, we found that n-3 DGs attenuate microgliosis and astrogliosis. Thus, n-3 DG emulsions are a superior, promising, and novel therapy for treating HIE.
This is a single-arm prospective trial. Participants perform self-skin exams using naked-eye criteria and will take smartphone clinical images (SCI) of each PSL of concern (PSLC). Participants will also take digital dermoscopy images (DDIs) and apply the Sklip System (integrating the Sklip Mole Scan Algorithm (SMSA) to each PSLC of concern in up to 14 days. Within up to 28 days of completing the at-home exams, participants will undergo an in-office visit full body skin exam (FBSE).
Patients with new-onset atrial fibrillation in sepsis have a high mortality rate and poor prognosis. At present, the pathogenesis of new-onset atrial fibrillation in sepsis has not been fully elucidated. Studies have shown that both sepsis and atrial fibrillation are closely related to NOD-like receptor protein 3 (NLRP3). NLRP3 inflammasome can not only induce the activation of caspase-1 and the subsequent release of cellular pro-inflammatory factors, but also participate in the occurrence and development of sepsis and promote the occurrence and development of atrial fibrillation. It is concluded that the NLRP3 inflammasome may play an important role in the occurrence and development of new-onset atrial fibrillation in sepsis. This paper summarized the current research progress on the structure and function of the NLRP3 inflammasome, its role in sepsis, its mechanism in promoting atrial fibrillation, the relationship between the NLRP3 inflammasome and new-onset atrial fibrillation in sepsis, the feasibility of studying new-onset atrial fibrillation in sepsis, and potential therapeutic targets for new-onset atrial fibrillation in sepsis. This review aims to provide a theoretical basis for future research on the mechanisms by which the NLRP3 inflammasome promotes new-onset atrial fibrillation in sepsis and possible therapeutic targets.
Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
Risk Summary

There are no adequate and well-controlled studies of iDose TR (travoprost intracameral implant) administration in pregnant women to inform a drug-associated risk. Subcutaneous administration of travoprost to pregnant mice and rats throughout the period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses.

Advise pregnant women of a potential risk to a fetus. iDose TR should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Data

Animal Data

An embryo-fetal development study was conducted in pregnant rats administered travoprost once daily at doses up to 10 mcg/kg by subcutaneous injection from gestation day (GD) 6 to 17, to target the period of organogenesis. At 10 mcg/kg, 116 times the maximum human ocular dose (MHOD) of 1 implant per eye, based on body surface area (BSA), assuming sustained travoprost release from the implant for 6 months or 0.0139 mcg/kg/day, travoprost was teratogenic in rats, evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, including fused sternebrae, domed head and hydrocephaly. Travoprost caused post-implantation loss at 10 mcg/kg. The fetal no observed adverse effect level (NOAEL) was 3 mcg/kg (34.5 times the maximum human ocular dose (MHOD) of 1 implant per eye, based on BSA).

An embryo-fetal development study was conducted in pregnant mice administered travoprost once daily by subcutaneous injection at doses up to 1 mcg/kg from GD 6 to 16, to target the period of organogenesis. Travoprost induced an increase in post-implantation losses and a decrease in fetal viability in mice at subcutaneous doses > 0.3 mcg/kg. The fetal NOAEL was 0.3 mcg/kg (1.7 times the MHOD based on BSA). The maternal NOAEL was 1 mcg/kg (5.8 times the MHOD based on BSA).

Pre/postnatal development studies were conducted in rats administered travoprost once daily by subcutaneous injection from GD 7 (early embryonic period) to postnatal Day 21 (end of lactation period). At doses of greater than or equal to 0.12 mcg/kg/day (1.4 times the MHOD based on BSA), the incidence of post-natal mortality was increased, and neonatal body weight was decreased. Neonatal development was also affected, evidenced by delayed eye opening, pinna detachment and preputial separation, and by decreased motor activity.
PURPOSE:To obtain a ultraviolet-absorbing skin cosmetic having high safety and light stability as well as excellent ultraviolet-absorbing effect and moisture retaining effect. CONSTITUTION:The characteristic of this skin cosmetic comprises containing extracts of a plant of Rutaceae Juss. The characteristic of this skin cosmetic is that the extracts of the plant of Rutaceae Juss. are extracts of Phellodendron Rupr. and/or Murraya Koen. exL. and/or Skimmia Thunb. The characteristic of this skin cosmetic comprises extracts obtained by extracting the plant with methanol or ethanol and then, re-extracting the extracts with ethyl acetate or butanol.
Potential subjects aged 5 to 12 years with picky eating symptoms consistent with an ARFID diagnosis, as determined by the Pica, ARFID, Rumination Disorder Interview, a semi-structured diagnostic interview, will be recruited via social media and local doctor's offices. Eligible subjects will complete informed consent and an intake session. Participants will then be randomized to an immediate treatment group, in which they will begin treatment the following week, or a 4-week waitlist condition, in which they will wait four weeks to begin treatment. All participants will have the opportunity to receive the treatment, ARFID Parent Training Program or "ARFID-PTP." ARFID-PTP was adapted from a seven-session parent-training for extremely picky eating behaviors to examine the efficacy of a two-session, virtual protocol on increasing food intake and decreasing selective eating. The two virtual treatment sessions will include psychoeducation, parent-training skills, and exposure protocol. There will be 5 major assessment time points: intake, end of treatment, 4-weeks post-treatment, 3-months post-treatment, and 6-months post-treatment.
BACKGROUND: There is no criterion to guide and evaluate the anastomosis of laparoscopic low anterior resection (LAR). We developed a new technique for precise anastomosis. This study endeavored to evaluate the effectiveness and safety of this new technology.
METHODS: Patients with mid-low rectal cancer who underwent laparoscopic LAR in our department were enrolled retrospectively between January 1, 2021 and July 1, 2023. During the LAR, the distance between the sacral promontory and the rectal stump was measured and used to determine the length of the sigmoid colon, which was preserved for anastomose. The demographic characteristics and short-term outcomes were analyzed.
RESULTS: Forty-nine patients (26 men, 23 women) with low and middle rectal cancer were retrospectively enrolled in the study. The distance of the tumor from the anal verge was 6.4 ± 2.7 cm. The operative time was 193 ± 42 min. All patients underwent precise anastomosis, among which 12 patients underwent freeing of the splenic flexure of the colon. According to our criteria, there was no redundant or tense state of the colon anterior to the sacrum after the anastomosis. Only one patient had a postoperative anastomotic leak (Grade B). All 15 patients receiving neoadjuvant chemoradiotherapy underwent terminal ileostomy. No postoperative death occurred within 30 days of the surgery. The median follow-up time in our study was 12 months. One patient developed a single metastasis in the right lobe of the liver in the eighth month after surgery and underwent microwave radiofrequency ablation, which did not recur in the four months of postoperative follow-up, and the rest of the patients survived disease-free without recurrence of metastasis.
CONCLUSIONS: Precise measurement of the proximal colon of the anastomosis can ensure accurate and convenient colorectal anastomosis and this may be a technique worthy of clinical application. However, its effectiveness needs to be further verified in a multicenter clinical trial.
More than 5.3 million individuals at risk for suicide seek treatment through emergency departments (EDs) each year despite the fact that EDs are not well suited for their care. Crisis Stabilization Centers (CSCs) have been proposed as a person-centered alternative to EDs. More than 600 CSCs nationwide operate 24 hours per day, accept walk-ins, provide care regardless of ability to pay, and partner with local law enforcement to divert suicidal patients from EDs. However, research outcomes on CSCs are mixed, likely associated with the fact that brief, recovery-oriented interventions with the potency to decrease suicide attempts and deaths are needed in CSCs but do not exist. Toward recovery, hope, recovery, interpersonal growth, values, and engagement (THRIVE) is a 60 minute intervention developed by the Principal Investigator and CSC stakeholders. THRIVE is uniquely tailored to CSC workflows and helps guests increase hopefulness, make meaning from stressful life events, and promote self-efficacy to prevent suicide attempts. In THRIVE, the guest is asked to narrate the suicide crisis, make meaning of the crisis through building an autobiographical timeline, and construct actionable future goals through an building an interactive meaningful living plan. THRIVE is conducted via a tablet so that all materials can be saved electronically in a HIPAA-compliant cloud to support providers in collaborating on care goals during and after discharge. The goal of this project is to fill a critical gap in the crisis stabilization literature by testing THRIVE as a novel solution to maximize the effectiveness of CSCs. This study will address the following aims: 1) Examine the feasibility, acceptability, and ecological validity of THRIVE as a unique fit for CSC guests (n = 30) and staff; 2) Conduct a pilot randomized trial (n = 150) to examine the degree to which THRIVE engages proposed recovery-oriented mechanisms of change relevant to the unique treatment philosophies of CSC settings; 3) As part of the pilot randomized trial, compare the outcomes of THRIVE + Usual Care (THRIVE + UC) to the outcomes of Usual Care (UC) delivered in the CSC (i.e., on recovery orientation, suicidal ideation, resolved suicide plans and preparation, treatment engagement, and acute psychiatric re-admissions). In Phase I (Aim 1), participants will be administered quantitative surveys after experiencing the THRIVE intervention. In Phase II (Aims, 2-3), participants in the RCT will be administered surveys at baseline, discharge, 1 month follow-up, and 3-month follow-up time points. CSCs represent the future of suicide-specific care and THRIVE is a novel intervention with the potential to impact more than 5.3 million individuals in a highly lethal group - suicidal individuals seeking care at EDs diverted to CSCs.
Patients will be randomized to receive study drug or placebo and randomization will occur stratified to each diagnostic category. All patients undergo preoperative echocardiograms to provide preoperative cardiac function data. The study drug or placebo will be provided in the operating room as an iv bolus just prior to cardiopulmonary bypass and as a bolus delivered on release of the aortic cross-clamp. This will be followed by iv for 12 hours. Operative data will be collected including CPB time, aortic cross-clamp time, length and degree of hypothermia. These data will be extracted from the anesthesia record.
PURPOSE: To obtain a preparation containing paeonification or its derivative as an active component, capable of suppressing the collagen synthesis especially in organs and useful for treating a disease showing a morbid state of extracellular MATRIX production accentuation such as hepatocirrhosis, interstitial lung disease, chronic renal failure, scleroderma or arterial sclerosis, etc. CONSTITUTION: This preparation contains paeoniflorin of a glucoside of the formula (G1c is a glucose residual group) or its derivative as an active component, and is an inhibitor against the synthesis of a heat shock protein (HSP47) having a molecular weight of 47 kilo dalton. Further, the synthesis inhibitor contains the active component in an amount of 0.01-99wt.%, preferably 0.1-80wt.%. The preparation is preferably administered at a normal daily dose of about 1mg to 10g in terms of paeoniflorin for an adult in one to 4 divided doses orally or parenterally. Paeoniflorin having the formula is preferably extracted, e.g. from SYAKUYAKU (root of Paeonia albiflora).
Techniques for tracking medical devices, for instance medical implants, are described herein. Medical devices can be tracked that are, for example, not directly marked with an identifier. In one embodiment, a device tracking application can execute on a computer system. Such a computer system can include one more computing devices that can optionally communicate with each other to send and receive information associated with medical devices. In accordance with one embodiment, a storage object image representative of a storage object is displayed on a display of a computer system. The storage object image can include a plurality of storage location areas that represent a plurality of storage locations within the storage object. Devices can be tracked based on the storage location areas of the storage object image.
For mirror therapy, a 50×40 cm mirror will be used. The patient will be positioned in a semi-sitting position at a 45° angle in bed, with the mirror placed on the side of the body where the access will be made. The arm with the fistula will be positioned behind the mirror. The position will be standardized so that the patient's thumb is 30 cm away from the mirror. The arm without the fistula will be supported with a pillow underneath to facilitate the patient's view in the mirror, positioned next to the patient. After observing their arm in the mirror for 15 minutes, the cannulation procedure will be performed.